Analyst consensus rating
ADARx Pharmaceuticals Analyst Rating: Strong Buy
Direct answer
ADARx Pharmaceuticals's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.75.
Forecast evidence checked November 19, 2026.
Get free ADARx Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $13.57
- Average price target
- $33.75
- High price target
- $36.00
- Low price target
- $32.00
- Low target gap
- +135.9%
- Target upside
- +148.8%
- High target gap
- +165.4%
- Target range width
- 29.5%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- November 19, 2026
- Valid through
- November 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ADARx Pharmaceuticals?
ADARx Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $33.75.
How far are ADARx Pharmaceuticals's low and high targets from the recorded price?
The low target implies +135.9%, while the high target implies +165.4%.
How many analysts are included in ADARx Pharmaceuticals's consensus?
The verified consensus includes 4 analysts.
How is ADARx Pharmaceuticals's target upside or downside calculated?
The average target of $33.75 is divided by the recorded price of $13.57, then one is subtracted to produce +148.8%. This does not guarantee a future return.
When was ADARx Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-19. The dataset is valid through 2026-11-26.